ESR1 and breast carcinoma: Dose response curves representing the efficacy of SP-1-303, SAHA, and Tamoxifen, along with 95% confidence intervals and margins of error, in each cell line were shown in S1–S5 Figs. It is clear that ER+ breast cancer cells are more sensitive to SP-1-303 than are cells from other breast cancer types.